Cargando…
BRAF V600E mutations in urine and plasma cell-free DNA from patients with Erdheim-Chester disease
Erdheim-Chester disease (ECD) is a rare histiocytosis with a high prevalence of BRAF V600E mutation (>50% of patients). Patients with BRAF-mutant ECD can respond to BRAF inhibitors. Unfortunately, the lack of adequate archival tissue often precludes BRAF testing. We hypothesized that cell-free DN...
Autores principales: | Janku, Filip, Vibat, Cecile Rose T., Kosco, Karena, Holley, Veronica R., Cabrilo, Goran, Meric-Bernstam, Funda, Stepanek, Vanda M., Lin, Patrick P., Leppin, Lorieta, Hassaine, Latifa, Poole, Jason C., Kurzrock, Razelle, Erlander, Mark G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4116506/ https://www.ncbi.nlm.nih.gov/pubmed/25003820 |
Ejemplares similares
-
Real‐World Toxicity Experience with BRAF/MEK Inhibitors in Patients with Erdheim‐Chester Disease
por: Saunders, Ila M., et al.
Publicado: (2019) -
Erdheim-Chester Disease
por: Yamamoto, Shinya, et al.
Publicado: (2019) -
FDA Approval Summary: Vemurafenib for the Treatment of Patients with Erdheim‐Chester Disease with the BRAFV600 Mutation
por: Oneal, Patricia A., et al.
Publicado: (2018) -
Vemurafenib for BRAF V600‐mutant Erdheim–Chester disease presenting with bilateral orbital involvement
por: Wang, Xiaomeng, et al.
Publicado: (2023) -
Unusual manifestation of Erdheim-Chester disease
por: Pan, Antony, et al.
Publicado: (2011)